Hybridoma technology produces monoclonal antibodies (mAb) by fusing a specific antibody-producing B cell with a myeloma cell, creating a hybrid cell known as a hybridoma. The hybridoma technique is considered to be very robust and can be used to isolate different types of antibodies possessing varied functionalities. This fusion allows for the immortalization of the antibody-producing cells, enabling continuous production of a single type of antibody. The resulting hybridomas are highly specific and uniform, making them valuable tools in various scientific and medical applications.

Hybridoma cell technology is crucial in the biotechnology and healthcare industries because it produces monoclonal antibodies with high specificity and consistency. These hybridoma cells are essential tools that precisely detect specific biomolecules, pathogens, or abnormal cells. In healthcare, medical research and personalized medicine, hybridomas are widely used for therapeutic purposes, such as targeted treatments for cancers, autoimmune diseases, and infectious conditions.

Hybridoma Techniques

1. Immunization of Host Animals

• Laboratory mice are typically used as host organisms.
• Mice are immunized with a specific antigen over several weeks to elicit a strong immune response.
• The goal is to stimulate B lymphocytes to produce antibodies against the antigen.

2. Isolation of Spleen B Cells

• After the final booster dose, mice are sacrificed, and their spleens are removed under sterile conditions.
• Spleen cells, rich in activated B cells, are isolated through mechanical disruption and filtration.

3. Fusion with Myeloma Cells

• The isolated B cells are mixed with immortal myeloma cells, deficient in antibody production but capable of indefinite division.

• Cell fusion is induced using fusogenic agents:

  • Polyethylene glycol (PEG): a widely used chemical fusogen that promotes membrane fusion.
  • Sendai virus: a biological agent that facilitates membrane merging.

4. Selection of Hybridomas

• The fused cell mixture is cultured in HAT (Hypoxanthine-Aminopterin-Thymidine) medium.

• This medium selectively allows only fused hybridomas to survive:

  • Unfused myeloma cells lack the enzymes needed to survive in HAT.
  • Unfused B cells naturally die after a few days in culture.

5. Cloning and Expansion

• Surviving hybridomas are subjected to limiting dilution cloning to isolate monoclonal populations.
• Each clone originates from a single hybridoma cell and produces a unique monoclonal antibody.

6. Screening for Desired Antibodies

• Clones are screened using assays such as:

  • ELISA (Enzyme-Linked Immunosorbent Assay)
  • Western blot
  • Flow cytometry

• Only clones producing antibodies with the desired specificity and affinity are selected for expansion.

7. Long-Term Culturing and Antibody Production

• Selected hybridomas are cultured in vitro for continuous monoclonal antibody production.
• These antibodies can be harvested from culture supernatants or scaled up using bioreactors.

Latest Innovations in Hybridoma Techniques

Single-Cell Cloning & Microfluidics

• Advances in single-cell cloning technologies enable the isolation and characterization of individual antibody-secreting cells, allowing for the identification of rare, high-affinity clones.
• Microfluidic devices offer precise control over small volumes of fluids, facilitating high-throughput screening of single cells.
• This technology enhances the efficiency and speed of hybridoma generation by enabling the more automated isolation and analysis of individual cells.

Improved Fusogens & Fusion Protocols

• New fusogens and fusion protocols enhance cell fusion efficiency, improving the chances of successful hybridoma formation.

  • One example of a fusogen commonly used in hybridoma production technology is polyethylene glycol (PEG).
  • PEG is a water-soluble polymer that facilitates the fusion of cell membranes by inducing a temporary destabilization of the lipid bilayers.
  • During the fusion process, PEG promotes the close apposition of the plasma membranes of B cells and myeloma cells, allowing for the merging of the two cell types and the formation of hybridomas.
  • Other fusogens, such as Sendai virus, have also been employed in hybridoma generation to achieve membrane fusion in a controlled and efficient manner.

Advanced Screening Techniques

• Advanced screening techniques, such as flow cytometry and microarray-based methods, enable rapid screening of a large number of hybridomas for antigen specificity and antibody characteristics.

  • Researchers implemented Bio-Layer Interferometry (BLI) on the OctetRED 384 platform for high-throughput screening of hybridoma clones based on dissociation rates, a kinetic analysis crucial for clone selection and characterization.
  • Unlike traditional enzyme-linked immunosorbent assays (ELISAs), which rely on antibody concentration and affinity, BLI allows for directly assessing dissociation rates.
  • The use of OctetRED facilitated the screening of 2000 hybridoma clones within 24 hours, identifying clones expressing high-affinity antibodies that conventional ELISA methods might overlook. This emphasizes the efficiency and discriminatory power of kinetic analysis in clone selection.

Benefits of the Hybridoma Technology

Enhanced Efficiency & Speed:

• Advanced methods enhance the speed and efficiency of hybridoma techniques by allowing the isolation and characterization of individual cells with higher precision.
• This accelerates the identification of high-affinity hybridomas, streamlining the overall process.

Reduced Manual Labor:

• Automation and high-throughput screening techniques significantly reduce the manual labor of the hybridoma technique.
• The use of microfluidics, for instance, minimizes reagent consumption, and incorporating automated workflows decreases the need for extensive hands-on work, leading to more resource-efficient processes.

Faster Drug Development:

• The quicker and more efficient generation of high-affinity hybridomas directly impacts drug development.
• Rapid identification and production of antibodies enable faster validation of potential therapeutic targets and accelerate drug development, ultimately contributing to advancements in healthcare.

Precision in Antibody Selection:

• Techniques like Bio-Layer Interferometry (BLI) provide a more nuanced approach to clone selection, considering dissociation rates and kinetic parameters.
• This precision in antibody characterization ensures the identification of clones producing antibodies with desirable qualities, leading to more effective applications.

Future Hybridoma Techniques

The ongoing advancement and refinement of hybridoma techniques are anticipated to wield considerable influence in biopharmaceutical. Since its introduction in 1975, hybridoma technology has transformed the monoclonal antibody production landscape and remains a favored approach. Its popularity stems from its capacity to maintain antibodies' natural pairing information and immune cells' intrinsic functions, making it a preferred method in the biopharmaceutical industry.

Continued Relevance in Biopharma

The biopharmaceutical industry's response to evolving technologies is evident in the ongoing progress of monoclonal antibody development. While high-throughput methods for generating monoclonal antibodies have emerged, the importance of hybridoma technology persists. Hybridoma technology continues to be favored due to its capacity to maintain innate immune cell functions and the natural pairing of information of antibodies.

Moreover, the advancement of hybridoma techniques has facilitated the continuous production of monospecific antibodies with consistent specificity, underscoring their crucial role in the biopharmaceutical sector.

Challenges in Technology Adoption

The biopharmaceutical industry holds a positive outlook for the future, yet it faces challenges, especially regarding adopting emerging technologies. Manufacturers in this sector often hesitate to embrace new technologies owing to the stringent demands of quality standards, the timelines associated with process development, and the necessity for robust manufacturing processes within the framework of current Good Manufacturing Practices (cGMPs).

Conclusions

Hybridoma techniques are a pivotal technology in biotechnology, offering a systematic approach to producing monoclonal antibodies with high specificity. The latest innovations, including single-cell cloning, microfluidics, and advanced screening techniques, can potentially revolutionize antibody-based solutions.

By enhancing the efficiency, speed, and precision of monoclonal antibody production – hybridoma technology, these advancements pave the way for the discovery of novel therapeutic targets, accelerated drug development, and the creation of more effective solutions, thereby significantly impacting the landscape of biotechnological applications.

recent-articles